Xilio Therapeutics, Inc. — Director's Dealing 2021

Oct 22, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Xilio Therapeutics, Inc. (XLO)
CIK: 0001840233
Period of Report: 2021-10-21

Reporting Person: LYNCH DANIEL (Director, 10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$5.51	2030-07-22	Common Stock (134797)		Direct
Stock Option (right to buy)	$5.89	2031-03-10	Common Stock (200597)		Direct

Footnotes

F1: The option was granted on July 23, 2020 for 134,797 shares. The underlying shares began vesting on June 11, 2020 and shall continue to vest in equal monthly installments thereafter until June 11, 2024.

F2: The option was granted on March 11, 2021 for 200,597 shares. The underlying shares began vesting on June 11, 2020 and shall continue to vest in equal monthly installments thereafter until June 11, 2024.